Last reviewed · How we verify
NCT04806126: HOME
Evaluation of a Virtual Home Dialysis Mentoring Program (Home)
trial in End Stage Renal Disease on Dialysis in 40 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Satellite Healthcare |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 19 March 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United States |
Conditions studied
- End Stage Renal Disease on Dialysis — all drugs for End Stage Renal Disease on Dialysis →
- Home Dialysis — all drugs for Home Dialysis →
Sponsor
Satellite Healthcare — full company profile →
Who can join
Eligibility, any sex, with End Stage Renal Disease on Dialysis or Home Dialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Investigator plans to establish a virtual platform for home dialysis physician mentoring with the intent to: 1. Formulate a practical, interactive, virtual curriculum in home dialysis 2. Provide dedicated video conferences in home dialysis mentorship 3. Measure knowledge awareness and attitudes towards home dialysis
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Implementation of a Virtual Home Dialysis Mentoring Program for Nephrologists.
Abra G, Poyan Mehr A, Chan CT, Schiller B. · · 2022 · cited 4× · PMID 35721601 · DOI 10.34067/kid.0000202022
Verify or expand the search:
- PubMed search for NCT04806126
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Renal Disease on Dialysis
Currently open trials in the same condition.
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT07016841 — Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins · recruiting
- NCT05654103 — Comparing Surgical and Endovascular Arteriovenous Fistula Creation · NA · recruiting
- NCT06483074 — Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients · Phase 2 · recruiting
- NCT06249932 — Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting
Other Satellite Healthcare trials
Trials by the same sponsor.
- NCT05400720 — Peer Support In Dialysis · NA · completed
- NCT05011136 — Physician Reimbursement Home Patients · completed
- NCT05022225 — Psychosocial Reasons for Transfer to In Center Hemodialysis in Home Dialysis Patients- A Focus Group Study · completed
- NCT04988568 — Experience of Patients Starting Hemodialysis · completed
- NCT04666844 — Predicting Transfers to Hemodialysis in Peritoneal Dialysis Patients Using the Surprise Question · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04806126 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Satellite Healthcare
- Last refreshed: 20 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04806126.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing